Prescribing information

 

_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

BRAF represents a novel therapeutic target for the treatment of advanced non-small cell lung cancer (NSCLC).1

 

Testing for BRAF in the UK

In England, BRAF testing can now be done as part of the next-generation sequencing (NGS) panel. For more information, go to the national genomic test directory for cancer in England.2

Visit the national genomic test directory for cancer in England

Icon of microscope.
 

 

Molecular characterisation of NSCLC marked a turning point in the treatment of lung tumours harbouring kinase alterations suitable for targeted drug inhibition.1

Among patients with driver mutations, outcomes for those treated with targeted therapies are prolonged compared with those who do not receive genotype-directed treatment.3

Pie chart showing the proportions of the types of NSCLC mutations.

 

Source: Kantar Health Cancer Impact; Multiple secondary sources for Biomarker splits 

WT, wild type

 

Mechanism of action of Tafinlar + Mekinist

Tafinlar (dabrafenib) + Mekinist (trametinib) target two different kinases in the MAPK pathway (BRAF and MEK1/2 respectively) to block the signalling that leads to abnormal cell division and growth.6,7

Combination therapy with Tafinlar + Mekinist results in prolonged inhibition of tumour growth compared with either drug alone in BRAF V600E-mutant tumours, both in vitro and in vivo.6,7

Diagram showing the mechanism of action of Tafinlar + Mekinist.

Adapted from Leonetti A, et al. Cancer Treat Rev 2018.1

 

 

For more information on Tafinlar + Mekinist please refer to the Summary of Product Characteristics and Patient Information Leaflets.

SmPC for Tafinlar

SmPC for Mekinist

PIL for Tafinlar

PIL for Mekinist

ALK, anaplastic lymphoma kinase; BRAF, a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, while the protein is more formally known as serine/threonine-protein kinase B-Raf; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinases; KRAS, a proto-oncogene that is part of the RAS/MAPK signalling pathway; MAPK, mitogen-activated protein (MAP) kinase; MEK, mekinist; MET, a tyrosine kinase receptor; NSCLC, non-small cell lung cancer; RAS, rat sarcoma; ROS, reactive oxygen species; V600E, mutation of the BRAF gene in which valine (V) is substituted by glutamic acid (E) at amino acid 60; WT, wild type.

References

  1. Leonetti A, et al. Cancer Treat Rev 2018;66:82–94.
  2. NHS England. National Genomic Test Directory for cancer. Available at: https://www.england.nhs.uk/publication/national-genomic-test-directories/ (Accessed June 2021).
  3. Planchard D, et al. Lancet Oncol 2016;17:984–993.
  4. Kantar Health Cancer Impact; Multiple secondary sources for Biomarker splits.
  5. Marchetti A, et al. J Clin Oncol 2011;29(26):3574–3579.
  6. Mekinist (trametinib) Summary of Product Characteristics.
  7. Tafinlar (dabrafenib) Summary of Product Characteristics. 
Rate this content: 
No votes yet
UK | August 2021 | 118703
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]